GleamWall
中文EN

NBIX NEUROCRINE BIOSCIENCES INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 914475 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY38.0%
TTM net income YoY64.1%
TTM EPS YoY60.9%
Revenue 3-yr CAGR27.5%
Net income 3-yr CAGR54.4%

Margins

Gross margin97.8%
Operating margin24.0%
Net margin19.0%
FCF margin28.1%
EBITDA margin24.8%

Returns

ROE20.4%
ROA14.2%
ROIC (approx.)22.7%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets31.1%
Debt / equity0.00x
Current ratio2.04x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.52x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.12B$959.00M$814.50M$805.50M$794.90M$687.50M$572.60M$627.70M
Cost of revenue$26.60M$23.20M$13.80M$17.60M$13.00M$10.30M$9.20M$9.30M
Gross profit$1.10B$935.80M$800.70M$787.90M$781.90M$677.20M$563.40M$618.40M
R&D expense$351.80M$326.70M$296.20M$258.20M$250.00M$244.30M$263.20M$185.60M
SG&A expense$366.30M$439.70M$318.50M$301.80M$291.60M$286.30M$276.50M$287.80M
Operating income$331.30M$151.50M$193.40M$210.90M$239.00M$145.60M$23.60M$142.00M
Interest expense$300,000$2.90M——$0$0——
Pretax income$283.70M$162.20M$246.80M$239.40M$291.80M$159.50M$14.70M$162.60M
Income tax$77.20M$17.80M$48.90M$85.70M$82.30M$52.00M$6.80M$59.50M
Net income$206.50M$144.40M$197.90M$153.70M$209.50M$107.50M$7.90M$103.10M
EBITDA$340.30M$159.90M$200.60M$217.30M$245.70M$151.90M$30.20M$148.20M
EPS (basic)2.031.431.97—2.111.090.08—
EPS (diluted)1.961.391.91—2.041.060.08—
Weighted avg. shares (diluted)105.20M104.20M103.40M—102.50M101.00M102.50M—
Balance sheet
Cash & equivalents$641.50M$332.40M$266.50M$713.00M$340.20M$264.00M$194.10M$241.00M
Short-term investments$96.40M$57.40M$1.05B$767.40M$774.60M$711.60M$749.40M$843.10M
Receivables$957.30M$887.00M$768.10M$686.80M$728.00M$595.70M$516.00M$479.10M
Inventory$66.10M$104.20M$64.50M$69.00M$69.30M$56.90M$59.10M$57.40M
Current assets$2.01B$1.64B$2.44B$2.52B$2.16B$1.75B$1.64B$1.72B
PP&E, net$92.20M$90.50M$90.90M$89.80M$97.30M$91.70M$87.00M$82.60M
Goodwill$500.60M$500.60M$6.00M$6.10M———$5.70M
Intangibles$2.19B$2.23B—$4.70M$35.70M$37.20M$36.40M$36.50M
Total assets$5.63B$5.36B$4.91B$4.63B$4.27B$3.89B$3.69B$3.72B
Current liabilities$984.60M$874.50M$831.70M$743.40M$638.00M$546.30M$522.90M$507.70M
Total liabilities$1.75B$1.67B$1.50B$1.38B$1.26B$1.20B$1.15B$1.13B
Shareholders' equity$3.88B$3.69B$3.41B$3.25B$3.00B$2.69B$2.54B$2.59B
Shares outstanding101.30M101.60M100.60M100.10M99.70M99.00M99.00M99.40M
Cash flow statement
Operating cash flow$395.20M$136.40M$145.80M$388.40M$227.50M$102.00M$64.80M$242.50M
Capital expenditure$11.60M$7.80M$9.10M-$2.40M$13.20M$12.50M$10.70M$7.30M
Free cash flow$383.60M$128.60M$136.70M$390.80M$214.30M$89.50M$54.10M$235.20M
Investing cash flow-$11.10M-$135.40M-$506.20M-$52.90M-$196.70M-$29.00M$14.20M-$68.30M
Financing cash flow-$75.00M$63.40M-$86.10M$37.30M$45.60M-$3.30M-$117.90M-$290.00M
Depreciation & amortization$9.00M$8.40M$7.20M$6.40M$6.70M$6.30M$6.60M$6.20M
Stock-based compensation$54.30M$65.00M$57.20M$58.60M$53.70M$52.80M$52.80M$66.40M
Share buybacks$92.10M$12.00M$54.00M$0$0$17.70M$150.00M$300.00M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.